Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alpha-2a (PegIFNα-2a)/ribavirin (RBV) or PegIFNα-2b/RBV, with respect to the proportion of treatment-naïve genotype 1 HCV-infected subjects with sustained virologic response (SVR) 12 weeks after the planned end of treatment (SVR12).
Inclusion criteria
- Hepatitis C Virus (HCV) in treatment naïve patients